PMID- 37224975 OWN - NLM STAT- MEDLINE DCOM- 20230705 LR - 20230705 IS - 1879-1298 (Electronic) IS - 0045-6535 (Linking) VI - 336 DP - 2023 Sep TI - Synthesis and electrochemical study of enzymatic graphene oxide-based nanocomposite as stable biosensor for determination of bevacizumab as a medicine in colorectal cancer in human serum and wastewater fluids. PG - 139012 LID - S0045-6535(23)01279-1 [pii] LID - 10.1016/j.chemosphere.2023.139012 [doi] AB - This work's goal was the fabrication of a graphene oxide-based nanocomposite biosensor for the determination of bevacizumab (BVZ) as a medicine for colorectal cancer in human serum and wastewater fluids. For the fabrication electrode, graphene oxide was electrodeposited on GCE (GO/GCE), and then DNA and monoclonal anti-bevacizumab antibodies were immobilized on the GO/GCE surface, respectively (Ab/DNA/GO/GCE). Structural characterization using XRD, SEM, and Raman spectroscopy confirmed the binding of DNA to GO nanosheets and the interaction of Ab with the DNA/GO array. Electrochemical characterization of Ab/DNA/GO/GCE using CV and DPV indicated immobilization of antibodies on DNA/GO/GCE and sensitive and selective behavior of modified electrodes for determination of BVZ. The linear range was obtained 10-1100 mug/mL, and the sensitivity and detection limit values were determined to be 0.14575 muA/mug.mL(-1) and 0.02 mug/mL, respectively. To verify the applicability of the planned sensor for determination of BVZ in human serum and wastewater fluid specimens, the outcomes of DPV measurements using Ab, DNA, GO, and GCE and the results of the Bevacizumab ELISA Kit for determination of BVZ in prepared real specimens showed good conformity between the outcomes of both analyses. Moreover, the proposed sensor showed considerable assay precision with recoveries ranging from 96.00% to 98.90% and acceptable relative standard deviations (RSDs) below 5.11%, illustrating sufficiently good sensor accuracy and validity in the determination of BVZ in prepared real specimens of human serum and wastewater fluids. These outcomes demonstrated the feasibility of the proposed BVZ sensor in clinical and environmental assay applications. CI - Copyright (c) 2023. Published by Elsevier Ltd. FAU - Wang, Xiaoli AU - Wang X AD - Department of Mechanical Engineering, Xi'an Jiaotong University City College, Xi'an, 710018, China. FAU - Mohammadzadehsaliani, Saman AU - Mohammadzadehsaliani S AD - Ophthalmology Department, Buraimi Hospital, Buraimi, Oman. FAU - Vafaei, Somayeh AU - Vafaei S AD - Department of Molecularf Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran. FAU - Ahmadi, Leila AU - Ahmadi L AD - Department of Chemistry, College of Sciences, Shiraz University, Shiraz, Iran. FAU - Iqbal, Amjad AU - Iqbal A AD - Department of Materials Technologies, Faculty of Materials Engineering, Silesian University of Technology, 44-100, Gliwice, Poland. FAU - Alreda, Baraa Abd AU - Alreda BA AD - Department of Medical Physics, Al-Mustaqbal University College, 51001, Hillah, Babylon, Iraq. FAU - Talib Al-Naqeeb, Bashar Zuhair AU - Talib Al-Naqeeb BZ AD - Anesthesia Technology Department, Al-Turath University College, Al Mansour, Baghdad, Iraq. FAU - Kheradjoo, Hadis AU - Kheradjoo H AD - Laboratory Department, Buraimi Hospital, Buraimi, Oman. Electronic address: hadiskheradjoo@gmail.com. LA - eng PT - Journal Article DEP - 20230522 PL - England TA - Chemosphere JT - Chemosphere JID - 0320657 RN - 0 (graphene oxide) RN - 0 (Wastewater) RN - 7782-42-5 (Graphite) RN - 9007-49-2 (DNA) SB - IM MH - Humans MH - Wastewater MH - Electrochemical Techniques/methods MH - *Graphite/chemistry MH - *Nanocomposites/chemistry MH - Electrodes MH - *Biosensing Techniques MH - DNA MH - *Colorectal Neoplasms OTO - NOTNLM OT - Bevacizumab OT - Electrochemical sensor OT - Graphene oxide OT - Human serum OT - Wastewater fluids COIS- Declaration of competing interest We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and company that could be construed as influencing the position presented in or the review of the manuscript entitled. No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication. I would like to declare on behalf of my co-authors that the work described was original research that has not been published previously, and not under consideration for publication elsewhere, in whole or in part. All the authors listed have approved the manuscript that is enclosed. EDAT- 2023/05/25 01:07 MHDA- 2023/07/05 06:42 CRDT- 2023/05/24 19:21 PHST- 2023/03/06 00:00 [received] PHST- 2023/05/11 00:00 [revised] PHST- 2023/05/21 00:00 [accepted] PHST- 2023/07/05 06:42 [medline] PHST- 2023/05/25 01:07 [pubmed] PHST- 2023/05/24 19:21 [entrez] AID - S0045-6535(23)01279-1 [pii] AID - 10.1016/j.chemosphere.2023.139012 [doi] PST - ppublish SO - Chemosphere. 2023 Sep;336:139012. doi: 10.1016/j.chemosphere.2023.139012. Epub 2023 May 22.